Abstract
The Dopamine Hypothesis has been the leading theory used to explain the mechanism of the clinical manifestation of schizophrenia symptoms for decades. It is unclear if excess dopaminergic activity is the primary pathophysiology causing psychosis or if this dopamine excess is triggered by upstream, downstream or neurodevelopmental abnormalities. A corollary hypothesis suggests that the glutamatergic system may be involved in the pathogenesis of schizophrenia, and that dysfunction of the glutamate system may actually lead to dopamine excess. The NMDA Receptor Hypofunction Hypothesis suggests that malfunctioning NMDA receptors may be the cause for the theoretically hypofunctioning glutamate system. This paper seeks to describe and discuss the potential underlying genetic vulnerabilities of the NMDA receptor and how aberrant genes coding for this receptor may lead to schizophrenia symptoms.
Keywords: NMDA receptor, schizophrenia, glutamate, genetics, Dopamine Hypothesis, neurodevelopmental abnormalities, ion channel, homeostasis, psychosis, psychiatric symptoms
Current Pharmaceutical Design
Title:Genetic Data Supporting the NMDA Glutamate Receptor Hypothesis for Schizophrenia
Volume: 18 Issue: 12
Author(s): Thomas L. Schwartz, Shilpa Sachdeva, Stephen M. Stahl
Affiliation:
Keywords: NMDA receptor, schizophrenia, glutamate, genetics, Dopamine Hypothesis, neurodevelopmental abnormalities, ion channel, homeostasis, psychosis, psychiatric symptoms
Abstract: The Dopamine Hypothesis has been the leading theory used to explain the mechanism of the clinical manifestation of schizophrenia symptoms for decades. It is unclear if excess dopaminergic activity is the primary pathophysiology causing psychosis or if this dopamine excess is triggered by upstream, downstream or neurodevelopmental abnormalities. A corollary hypothesis suggests that the glutamatergic system may be involved in the pathogenesis of schizophrenia, and that dysfunction of the glutamate system may actually lead to dopamine excess. The NMDA Receptor Hypofunction Hypothesis suggests that malfunctioning NMDA receptors may be the cause for the theoretically hypofunctioning glutamate system. This paper seeks to describe and discuss the potential underlying genetic vulnerabilities of the NMDA receptor and how aberrant genes coding for this receptor may lead to schizophrenia symptoms.
Export Options
About this article
Cite this article as:
Thomas L. Schwartz, Shilpa Sachdeva, Stephen M. Stahl , Genetic Data Supporting the NMDA Glutamate Receptor Hypothesis for Schizophrenia , Current Pharmaceutical Design 2012; 18 (12) . https://dx.doi.org/10.2174/138161212799958594
DOI https://dx.doi.org/10.2174/138161212799958594 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Driving Cellular Plasticity and Survival Through the Signal Transduction Pathways of Metabotropic Glutamate Receptors
Current Neurovascular Research Why Should We Keep the Cerebellum in Mind When Thinking About Addiction?
Current Drug Abuse Reviews Methadone Maintenance Treatment and Cognitive Function: A Systematic Review
Current Drug Abuse Reviews Lipid Nanocarriers and Molecular Targets for Malaria Chemotherapy
Current Drug Targets Targets for the Treatment of Erectile Dysfunction: Is NO/cGMP Still the Answer?
Recent Patents on Cardiovascular Drug Discovery Post-stroke Depression Therapy: Where are we now?
Current Neurovascular Research Possible Consequences of Blocking Transient Receptor Potential Vanilloid 1
Current Pharmaceutical Biotechnology Chvostek's Sign in Paediatric Practice
Current Pediatric Reviews An <i>OTOF</i> Frameshift Variant Associated with Auditory Neuropathy Spectrum Disorder
Current Genomics Brain Derived Neurotrophic Factor and Cognitive Status: The Delicate Balance Among People Living with HIV, with and without Alcohol Abuse
Current HIV Research Tryptophan Catabolites and Migraine
Current Pharmaceutical Design Effects of Psychoactive Substances in Schizophrenia – Findings of Structural and Functional Neuroimaging
Current Topics in Medicinal Chemistry Nicotinic Receptors and the Treatment of Attentional and Cognitive Deficits in Neuropsychiatric Disorders: Focus on the α7 Nicotinic Acetylcholine Receptor as a Promising Drug Target for Schizophrenia
Central Nervous System Agents in Medicinal Chemistry Ginkgo biloba Extract 761: A Review of Basic Studies and Potential Clinical Use in Psychiatric Disorders
CNS & Neurological Disorders - Drug Targets The Long-Term Impact of Early Adversities on Psychiatric Disorders: Focus on Neuronal Plasticity
Current Pharmaceutical Design Dopamine Receptor Interacting Proteins: Targeting Neuronal Calcium Sensor-1/D2 Dopamine Receptor Interaction for Antipsychotic Drug Development
Current Drug Targets Radiopharmaceuticals in Neurological and Psychiatric Disorders
Current Clinical Pharmacology Translational Challenge Models in Support of Efficacy Studies: Neurobehavioral and Cognitive Changes Induced by Transcranial Magnetic Stimulation in Healthy Volunteers
CNS & Neurological Disorders - Drug Targets Ketamine as Antidepressant? Current State and Future Perspectives
Current Neuropharmacology Neuritin, A Neurotrophic Factor in Nervous System Physiology
Current Medicinal Chemistry